Fig. 1 · Structure

Documents & Downloads

Probucol

Cat. No. A11751 CAS 23288-49-5
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
THP-1 IC50 0.6 μM Antioxidant activity in human THP1 cells assessed as inhibition of macrophage-mediated LDL oxidation after 24 hrs in presence of CuSO4 by TBARS assay [PMID: 30015075]

Probucol Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Probucol from 3 published references. In vitro models include HEK293 cells with endogenous Parkin present at low levels; rabbit aortic smooth muscle cells. In vivo models include obese Zucker rats.

Probucol In Vitro Studies

In HEK293 cells with low endogenous Parkin levels, Probucol increased LC3-II levels under basal conditions. In rabbit aortic smooth muscle cells, Probucol induced HO-1, whereas vitamin E failed to induce it. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Basal LC3-II levels in HEK293 cells

Cell-based study · HEK293 cells with endogenous Parkin present at low levels [1]

HEK293 cells with low endogenous Parkin levels received Probucol at 1 μM, with DMSO as the control. LC3-II levels increased following treatment under basal conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LC3-II levelsReported result LC3-II levels increased following probucol treatment under basal conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Probucol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Probucol increases LC3 lipidation and lysosome abundance (S81, S83); Table 1 (T1.r15)

LC3-II levels: LC3-II levels; comparator: DMSO — Results > Probucol increases LC3 lipidation and lysosome abundance (S81)

HO-1 induction in rabbit aortic smooth muscle cells

Cell-based study · rabbit aortic smooth muscle cells [2]

Rabbit aortic smooth muscle cells were cultured with Probucol at 50 μM for 24 h, with HO-1 mRNA assessed by real-time RT-PCR. Probucol induced HO-1, whereas vitamin E failed to do so.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HO-1 mRNA assessed by real-time RT-PCRReported result Unlike probucol, vitamin E failed to induce HO-1 in vascular smooth muscle cells in vitro[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
24 h
Method
cultured
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Probucol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS (S36); Figure 5. legend (S149)

HO-1 mRNA assessed by real-time RT-PCR: HO-1 mRNA assessed by real-time RT-PCR; comparator: vehicle (control) — RESULTS (S36); Figure 5. legend (S149)

Probucol In Vivo Studies

In obese Zucker rats undergoing carotid balloon injury and external carotid artery ligation, Probucol treatment yielded a reported intimal area of 0.05 ± 0.01 mm2, with the compound effect isolated by comparison with Obese. In female SD rats with bilateral ovariectomy-induced osteoporosis, oral Probucol increased BMD, with the compound effect isolated by comparison with the OVX group. [2,3]

Intimal area in obese Zucker rats

Animal study · obese Zucker rats (n = 9) [2]

Obese Zucker rats received Probucol in fed chow at 1% (wt/wt) for 4 wk, with carotid balloon injury after 2 wk. The design included left common carotid artery balloon injury and external carotid artery ligation, with the compound effect isolated by comparison with Obese. The reported intimal area was 0.05 ± 0.01 mm2.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intimal area (mm2)Intimal area 0.05 ± 0.01 mm2[2]

Conditions shared by the study groups

Route
fed chow
Treatment course
administered for 4 wk, with carotid balloon injury performed after 2 wk
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Probucol 1% (wt/wt)Obese(n = 9)0.05 ± 0.01 mm2[2]
Probucol 1% (wt/wt)
Model: obese Zucker rats (n = 9)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Probucol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Animal models. (S71, S72, S75); Table III. legend (S165); Table III. (T3.h1, T3.r1)

Intimal area (mm2): Intimal area (mm2); comparator: Obese(n = 9) — Table III. (T3.h1, T3.r1)

Probucol 1% (wt/wt) · MATERIALS AND METHODS > Animal models. (S72); Table III. legend (S165); Table III. (T3.h1, T3.r1)

Bone mineral density in ovariectomized rats

Animal study · Three-month-old female SD rats; bilateral ovariectomy-induced osteoporotic rat model; n = 5 per group [3]

Female SD rats with bilateral ovariectomy-induced osteoporosis received Probucol by oral gavage at 3.5 mg/kg body weight per day for 12 weeks. BMD increased, with the compound effect isolated by comparison with the OVX group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BMDReported result increased BMD; (P < 0.05)[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
12 weeks of treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Probucol 3.5 mg/kg body weight per dayOVX groupincreased BMD; (P < 0.05)[3]
Probucol 3.5 mg/kg body weight per day
Model: Three-month-old female SD rats; bilateral ovariectomy-induced osteoporotic rat model; n = 5 per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Probucol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Experimental animals (S30, S31, S35); Results > Osteoporosis animal model (S67); Results > Micro-CT evaluation (S68, S70, S71); Fig. 3 legend (S101)

BMD: BMD; comparator: OVX group — Results > Micro-CT evaluation (S70, S71)

Probucol 3.5 mg/kg body weight per day · Materials and methods > Experimental animals (S35); Results > Micro-CT evaluation (S68, S71)

Specifications

Manufacturer Adooq Bioscience
CAS Number 23288-49-5
Formula C31H48O2S2
Molecular Weight 516.84
SMILES
CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 92 mg/mL (178 mM)
Water Insoluble
Ethanol 92 mg/mL (178 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Probucol Research References

  1. [1] Moskal N, Visanji NP, Gorbenko O, et al. An AI-guided screen identifies probucol as an enhancer of mitophagy through modulation of lipid droplets. PLoS Biol (2023). PMID: 36862640 DOI: 10.1371/journal.pbio.3001977 Source material
  2. [2] Wu BJ, Kathir K, Witting PK, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med (2006). PMID: 16606673 DOI: 10.1084/jem.20052321 Source material
  3. [3] Tao ZS, Li TL, Wei S. Probucol promotes osteoblasts differentiation and prevents osteoporosis development through reducing oxidative stress. Mol Med (2022). PMID: 35764958 DOI: 10.1186/s10020-022-00503-7 Source material

Added to your cart

View Cart Checkout
Loading...